Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

740 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.
Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A, Botto B, Chiappella A, Chiarenza A, Pinto A, De Renzo A, Zaja F, Castellino C, Bari A, Alvarez De Celis I, Evangelista A, Parvis G, Gamba E, Lobetti-Bodoni C, Ciccone G, Rossi G. Vitolo U, et al. Among authors: de angelis f, de renzo a. J Clin Oncol. 2013 Sep 20;31(27):3351-9. doi: 10.1200/JCO.2012.44.8290. Epub 2013 Aug 19. J Clin Oncol. 2013. PMID: 23960180 Clinical Trial.
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi. Ladetto M, et al. Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1. Blood. 2013. PMID: 24085766 Free article. Clinical Trial.
Follicular lymphoma.
De Angelis F, Foà R. De Angelis F, et al. Exp Oncol. 2012 Dec;34(4):380-3. Exp Oncol. 2012. PMID: 23303004 Review. No abstract available.
Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma.
Cavalieri E, Matturro A, Annechini G, De Angelis F, Frattarelli N, Gentilini F, Grapulin L, Sacco M, Torelli F, Vignetti M, Mandelli F, Foà R, Pulsoni A. Cavalieri E, et al. Among authors: de angelis f. Leuk Lymphoma. 2009 Nov;50(11):1803-8. doi: 10.3109/10428190903254383. Leuk Lymphoma. 2009. PMID: 19860621 Clinical Trial.
Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response.
Latagliata R, Romano A, Mancini M, Breccia M, Carmosino I, Vozella F, Montagna C, Volpicelli P, De Angelis F, Petrucci L, Serrao A, Molica M, Salaroli A, Diverio D, Alimena G. Latagliata R, et al. Among authors: de angelis f. Leuk Lymphoma. 2016;57(1):99-102. doi: 10.3109/10428194.2015.1043548. Epub 2015 Oct 5. Leuk Lymphoma. 2016. PMID: 25997497
Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia.
Latagliata R, Carmosino I, Vozella F, Volpicelli P, De Angelis F, Loglisci MG, Salaroli A, De Luca ML, Montagna C, Serrao A, Molica M, Diverio D, Nanni M, Mancini M, Breccia M, Alimena G. Latagliata R, et al. Among authors: de luca ml, de angelis f. Hematol Oncol. 2017 Jun;35(2):232-236. doi: 10.1002/hon.2274. Epub 2015 Dec 9. Hematol Oncol. 2017. PMID: 26648184
740 results